MRINZ Deputy Director Paul Young Elected as Fellow of the Royal Society Te Apārangi
We are thrilled to announce that Deputy Director Professor Paul Young has been elected as a Fellow of the Royal Society Te Apārangi, an honour recognising his exceptional contributions to intensive care medicine and clinical trial design.
Each year, the Royal Society Te Apārangi elects new Ngā Ahurei a Te Apārangi Fellows, celebrating researchers, scholars, and innovators who have demonstrated excellence in their respective fields. Fellowship represents distinction in research, scholarship, or the advancement of knowledge at the highest international level, and Fellows may use the post-nominal ‘FRSNZ’ in recognition of this achievement.
Professor Young is internationally regarded as a leader in critical care research. His work has shaped clinical practice worldwide, challenging traditional approaches and pioneering evidence-based improvements in the management of critically ill patients. Paul’s research spans a broad spectrum of intensive care medicine, including oxygen therapy, intravenous-fluid resuscitation, physiotherapy, blood transfusion, nutrition, sepsis management, trauma and traumatic brain injury, ulcer prevention, and fever treatment. Through his innovative and robust trial designs, he has provided critical insights that have directly improved patient outcomes on a global scale.
Distinguished Professor Geoff Chase FRSNZ, Chair of the Academy Executive Committee, highlighted the significance of this year’s elected Fellows, noting their impact across a diverse range of disciplines.
“The newly-elected Ngā Ahurei Fellows have made contributions to knowledge and have had impact at the highest levels in their different fields and across disciplinary boundaries. Their election demonstrates the excellence of New Zealand research, innovation, and scholarship and shows the contribution our nation’s Fellows make on the world stage.”
The MRINZ congratulates Professor Young on this well-deserved recognition and celebrates his ongoing commitment to advancing critical care medicine for the benefit of patients in Aotearoa New Zealand and beyond.
